Trial Profile

A retrospective study evaluating switching and discontinuation rates of apixaban, rivaroxaban or dabigatran therapy in patients with nonvalvular atrial fibrillationin in the US

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 23 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
Indications Stroke
Focus Adverse reactions; Therapeutic Use
Sponsors Bristol-Myers Squibb; Pfizer

22 May 2019 Results evaluating the association of switching to another oral anticoagulant vs. continuing with apixaban treatment among elderly patients with nonvalvular atrial fibrillation presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
13 Dec 2018 New trial record
14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com